Verséa
Verséa
Connect With Us
Home
About
About Us
Mission & Values
Our History
Our Standards
Leadership
Scientific Advisors
Careers
Business Units
Diagnostics
POC Professional
OTC Consumer
Virtual Health
Therapeutics
Biologics
Wellness
Ophthalmics
T-POC Testing Platform
Biovance 3L Ocular
Resources
Discovery
VCX™ Discovery Platform
AgroTech
Partnerships
News
Corporate
Diagnostics
Therapeutics
Ophthalmics
Discovery
Home
News2
All Posts
Verséa™ Biologics at the North American Neuromodulation Society 26th Annual Meeting
Verséa™ Ophthalmics at the Hawaii Eye 2023
Hear from the Experts on New Point-of-Care Testing & Therapeutic Innovations in Eye Care
Verséa™ Ophthalmics – proud sponsor of 2022 CEDARS/ASPENS Annual Meeting
Verséa™ Ophthalmics featured at the Eyes On 2023 Corporate Exhibit Hall Interview series
Verséa™ Ophthalmics President, Dr. Rob Sambursky, interviewed by Ophthalmology Times
Verséa™ Ophthalmics is presenting at the American Academy of Optometry (AAOpt) Meeting 2022
Verséa Holdings, Inc. Launching Verséa AgroTech and its proprietary Extended Shelf-life Packaging System at the IFPA Global Produce & Floral Show
Verséa Holdings, Inc. is Launching Verséa Health and Verséa Easy Lab™ at the NACS Show 2022
Verséa™ Ophthalmics is Launching Novel, Point-of-Care, Tear-Based Diagnostic Test Platform at the AAO 2022
Verséa Donates COVID-19 Test Kits to the University of South Florida (USF), Worth $1.1M
Verséa Searching For Brightest Students and Recent Graduates at the University of Tampa to Join Paid Internship Program
Verséa™ Ophthalmics Signs Exclusive Global Commercialization Agreement With AXIM® Biotechnologies for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. announced as a Tampa Bay Business Journal 40 under 40 honoree
Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President to lead the company’s expansion into the ophthalmic market
BA.4, BA.5, two new Omicron variants detected in the U.S., could spark another COVID wave
Successful first validation test on VCX™ Discovery Platform at UCSD Biomedical Lab
New Omicron Subvariant BA.2 Concern: More Contagious and Found in 48 States
Cannabinol (CBN) shows unique therapeutic potential in glaucoma
2 new COVID symptoms reported for BA.2 omicron variant
Omicron variants – Statement from the WHO
New Study Identifies Top-Performing Point-of-Care COVID-19 Tests
CareStart EUA Authorization